Pfizer confirms it is evaluating Korea operations amid job cut rumours

By Gareth Macdonald

- Last updated on GMT

Pfizer confirms it is talking with Korea labour unions
Pfizer confirms it is talking with Korea labour unions

Related tags Trade union Employment

Pfizer has confirmed it is in discussion with labour unions in Korea as part of an evaluation of its business in the country.

News reports last​ week suggested the US drugmaker is planning to lay off staff at its Pfizer Korea subsidiary, which currently employs 750, as part of an efficiency drive.

Pfizer spokesman Andrew Topen told us the firm is evaluating its business in Korea and based on this review “will implement an early retirement program targeting employees across the entire organization​.”

He added that: “No specific discussions or plans have been made regarding the target, size and timing of the planned early retirement program, and the management team is currently in discussions with the labour union.​”

Topen also said that “We are confident that these changes will enhance our competitiveness and allow us to invest in areas that derive the greatest value for the communities we serve​.”

He added that: "During this process, we will ensure that all impacted colleagues are treated with utmost respect and fairness​."

Korean growth

Pfizer Korea generated revenue of 628bn won ($534m) in 2014, which was up 4.8% on the previous year.

The labour union that represents the majority of Pfizer Korea’s employees confirmed it was in talks with the US drugmaker.

The organisation told the Korea Times "negotiations are underway between labor and management," ​adding that "We will cooperate with management if layoffs are deemed necessary.

However, the Union also warned that: “We will oppose management if it pushes layoffs forward without justifiable reasons​."

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us


View more